Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone antibiotic presented as an oral tablet for oral use. It treats infections caused by susceptible Gram‑positive bacteria, including MRSA and VRE, in adult patients. GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is used to treat serious infections caused by Gram‑positive bacteria, particularly those resistant to other agents. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates the pathogen and resolves infection. - Vancomycin‑resistant Enterococcus (VRE) infections: provides an effective oral option for resistant strains. - Community‑acquired bacterial pneumonia: targets susceptible organisms and improves respiratory outcomes. - Skin and soft‑tissue infections caused by susceptible Gram‑positive bacteria: reduces bacterial load and promotes healing.

Adverse reactions may occur with linezolid therapy and should be monitored.

Common Side Effects: - Nausea - Diarrhea - Headache - Metallic taste

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome

Use linezolid with caution in specific clinical situations and monitor patients accordingly. - Renal impairment: adjust monitoring as renal function may affect drug clearance. - Hepatic impairment: assess liver function before and during therapy. - Hematologic monitoring: perform regular blood counts to detect cytopenias. - Concomitant serotonergic agents: avoid or monitor for serotonin syndrome. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Linezolid can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased risk of serotonin syndrome. - Rifampin: markedly reduces linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect, monitor INR. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk, observe for signs of hemorrhage.